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Uric acid is strongly associated with cardiovascular and renal
disease, but is usually not considered to have a causal role.
However, recent experimental, epidemiological, and clinical
studies provocatively suggest that uric acid may contribute
to the development of hypertension, metabolic syndrome,
and kidney disease in some patients. Clinical studies are
urgently needed to examine this important possibility.
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Following the discovery by Garrod in the early 1800s that
hyperuricemia was the cause of gout, hyperuricemia was
proposed to have a causal role in a variety of cardiovascular
and renal conditions, including hypertension (Frederick
Mahomed), arteriolosclerosis (Henri Huchard), kidney
disease (Garrod and George Johnson), and heart disease
(Peter Hood). This was not surprising, as natural history
showed that 25–50% of gouty subjects had hypertension, 75%
were obese, 25% died with kidney failure, and 90% developed
cardiac disease, making gout the most important cardio-
vascular risk factor then known. By the mid-1900s, however,
the causal nature of uric acid in these conditions was
questioned, as it was recognized that the association of
gout with cardiovascular disease might simply reflect that
gout and cardiovascular complications have similar risk
factors (obesity, kidney disease, etc). This was addressed in
epidemiologic studies by asking whether uric acid was an
independent risk factor for cardiovascular and renal disease,
while controlling for other known risk factors such as hyper-
tension and metabolic syndrome. Some studies continued to
find uric acid an independent risk factor; however, others
could not. The inconclusiveness of the data, the supposi-
tion that soluble uric acid was biologically inert or even
an antioxidant, and the finding that the increase in uric
acid might be secondary to either a decrease in glomerular
filtration rate or the presence of hyperinsulinemia, all led to
the conclusion that uric acid was likely not a true cardio-
vascular or renal risk factor.1 Consequently, the uric acid
measurement was removed from the routine blood panel,
recommendations were made not to measure it routinely
in patients with cardiovascular or renal disease, and it was
deleted as a risk factor from the list provided by most
cardiovascular and renal societies. A ‘requiem’ for uric acid as
a renal risk factor was celebrated in this very journal,2 and
uric acid was laid to rest.
An ‘unearthing’ of uric acid as a cardiovascular and renal
risk factor occurred in the late 1990s when it was recognized
that there were certain assumptions that had been made with
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the various analyses.3,4 For example, uric acid need not be
an independent risk factor for cardiovascular disease in
order to be a causal risk factor. Thus, if uric acid caused
hypertension or kidney disease, it would not necessarily be
independent of these factors as a cardiovascular risk factor
(similar to the fact that hypertension is not independent of
left ventricular hypertrophy as a risk for cardiac death).4
Similarly, the finding that a decreased glomerular filtration
rate caused urate retention did not rule out the possibility
that the rise in uric acid might contribute to the subsequent
renal decline.3 Perhaps, most importantly, the conclusions
that uric acid was not important had never been tested by
direct experimental studies in animals or cell culture.3,4
Recent studies have raised the exciting possibility that
uric acid may indeed have a contributory causal role in
cardiovascular and renal disease. A brief summary of the
current state of knowledge is presented. Due to the nature of
the review, only select references are provided.
STUDIES OF THE IN VITRO EFFECTS OF URIC ACID
Soluble uric acid is not inert after all, but has been found to
have many biological properties. A major beneficial property
is its ability to act as an aqueous antioxidant. Some studies
suggest that, along with ascorbate, urate may be one of the
most important antioxidants in plasma. Uric acid will react
with a variety of oxidants, particularly peroxynitrite, and will
undergo subsequent oxidation through a series of reactions
resulting in the formation of allantoin. The ability of urate
to react with oxidants has been shown to have a beneficial
role on vascular cells in tissue culture under some condi-
tions associated with oxidative stress,5 and this has led to the
notion that a rise in uric acid in cardiovascular disease might
represent a compensatory attempt of the host in response to
the oxidative stress known to occur.6
In contrast, soluble uric acid has also been found to have
a wide variety of deleterious effects on vascular cells. Uric
acid has been found to enter vascular smooth muscle cells,
via specific organic anion transporters and activate intra-
cellular mitogen-activated protein kinases (such as p38 and
extracellular signal regulated protein kinase), and nuclear
transcription factors (nuclear factor-kappa B and activator
protein-1), resulting in a proliferative and proinflammatory
phenotype: vascular smooth muscle cells produce growth
factors (platelet-derived growth factor), vasoconstrictive sub-
stances (cyclooxygenase-2 induced thromboxane and angio-
tensin II), proinflammatory molecules (C-reactive protein
and monocyte chemoattractant protein), and the type I
angiotensin II receptor7–10 (unpublished data). Uric acid
also has profound effects on endothelial cells, resulting in
an inhibition of proliferation and migration, the stimulation
of C-reactive protein, and the inhibition of nitric oxide
release.10,11
The mechanism by which urate activates vascular cells
is being actively studied in our laboratory. One potential
mechanism relates to the discovery that the reaction of
uric acid with oxidants results in the release of a variety of
degradation products that are biologically free radicals.12 It is
interesting that antioxidants can block the effect of uric acid
on vascular smooth muscle cells.8 Currently, we are trying
to identify these radicals and determine if they are being
produced in vivo.
Studies in experimental models of hyperuricemia have
also provided major insights into potential pathogenic roles
of uric acid in renal and cardiovascular disease. These are
summarized below (Figure 1), along with recent clinical
studies.
DISEASES IN WHICH URIC ACID MAY HAVE A CONTRIBUTORY
ROLE
Essential hypertension and arteriolosclerosis
An exciting observation was the finding that experimental
hyperuricemia in rats results in the development of
hypertension. This occurs in two steps, with the first phase
driven by a fall in nitric oxide and an activation of the renin
angiotensin system, and with the second phase driven by
uric acid mediated renal microvascular disease.7,13 The renal
microvascular disease was shown to occur independently of
hypertension and clinically resembled the renal arteriolo-
sclerosis lesion of human hypertension.14 Consistent with
this finding have been a large number of epidemiological
studies reporting that an elevated uric acid is an independent
predictor of hypertension (reviewed in Johnson et al.15).
In all studies reported, uric acid has been an independent
risk factor, and in all studies the relationship of uric acid
with blood pressure has been dose-dependent, linear, and
consistent.15 Studies of new onset essential hypertension
in adolescents have reported an elevation of uric acid
(45.5 mg/dl) in 90% of hypertensive subjects versus 0% of
controls, and the relationship of uric acid with hypertension
was linear and dramatic (r¼ 0.8).16 In preliminary studies,
the lowering of uric acid resulted in the normalization of
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Figure 1 | Uric acid as a potential initiator of the cardiovascular
and renal disease epidemic. According to the model, an elevated
uric acid induced by diet (fructose, purines, or lead exposure) may
have a role in initiating hypertension, arteriolosclerosis, kidney
disease, insulin resistance, and hypertriglyceridemia. However, once
renal microvascular disease develops, the kidney will also drive the
hypertension; once obesity occurs, the fat-laden adipocytes will
promote continued insulin resistance, and one kidney disease is
manifest, the kidney will also drive progression. Uric acid may thus be
viewed as both an initiator and accomplice in driving the epidemic.
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Currently, there are two NIH trials ongoing to determine the
effect of lowering uric acid in the hypertensive adolescent,
and in the African American receiving diuretics for stage I
hypertension.
Metabolic syndrome
An interesting observation relates to the finding that the
ingestion of fructose, present in various sweeteners and sugar,
is strongly associated with the development of the metabolic
syndrome and the ongoing obesity epidemic.18 Fructose is
the only sugar that causes a rise in uric acid, and it does so
rapidly following ingestion. We hypothesized that the rise in
uric acid could have a role in the development of insulin
resistance through a urate-induced inhibition of endothelial
nitric oxide. A decrease in endothelial nitric oxide bioavail-
ability would counter the effects of insulin, which acts in
part by stimulating blood flow to skeletal muscle via nitric
oxide.19 Subsequently, we found that lowering uric acid
prevented or improved most features of the metabolic
syndrome in fructose-fed rats, including the prevention of
hyperinsulinemia, hypertriglyceridemia, hypertension, and
weight gain.20 Studies in humans have also found that uric
acid is a potent predictor of both hyperinsulinemia19 and
weight gain,21 and an elevated uric acid is observed in the
vast majority of subjects with metabolic syndrome. Clinical
studies are now being planned to determine if lowering
uric acid may be able to prevent the development of this
important medical problem.
Chronic kidney disease
Experimental studies demonstrated that hyperuricemia
caused the slow development of kidney disease, with the
development of albuminuria, microvascular disease, glomer-
ulosclerosis, and tubulointerstitial fibrosis.22 Hyperuricemia
was also found to accelerate renal disease of other etiologies,
particularly the remnant kidney model.9 A variety of mecha-
nisms were identified, including the stimulation of intrarenal
renin expression with renal hypertrophy, glomerular hyper-
trophy, acceleration of intrarenal microvascular disease, and
the development of glomerular hypertension and renal
vasoconstriction.9,22,23 Micropuncture studies demonstrated
that the development of glomerular hypertension was largely
due to the induction of preglomerular vascular disease that
altered renal autoregulation.23 Recent clinical studies have
also confirmed that uric acid is a major independent risk
factor for the development of renal disease both in the
normal population and in subjects with kidney disease
due to immunoglobulin A nephropathy. In one study of
the general population, hyperuricemia carried a greater
risk than proteinuria for the subsequent development of
renal insufficiency.24 Recently, a prospective controlled trial
examined the effect of lowering uric acid in patients
with chronic kidney disease and hyperuricemia.25 Subjects
in whom uric acid was lowered (from 9.75 to 5.8 mg/dl)
showed less renal progression (16%) versus controls (46%)
over the 1-year follow-up, and this was associated with an
11 mm Hg fall in systolic blood pressure in the treated group
versus no change in systolic blood pressure in the control
group.25 While these observations are exciting, additional
confirmation is needed.
Transplant-associated kidney disease
Hyperuricemia is common in transplant patients and is a
side effect of calcineurin inhibition. Interestingly, several
experimental studies suggest that hyperuricemia mimics
and exacerbates cyclosporine nephropathy,26 whereas lower-
ing uric acid may have a renoprotective role.27 Recently, the
lowering of uric acid in liver transplant subjects was reported
to improve renal function.28 It is also of interesting that the
induction of experimental hyperuricemia, particularly in the
remnant kidney model, is histologically identical to chronic
allograft nephropathy.9 This raises the interesting hypothesis
that hyperuricemia may be an important antigen-indepen-
dent risk factor for this condition, which is the major cause of
late allograft loss. Indeed, new onset gout in the renal trans-
plant patient has recently been found to be an independent
risk factor for both death and graft loss.29
Other renal and cardiovascular syndromes
Several studies also suggest that uric acid may have a contri-
butory role in pre-eclampsia,30 in intrauterine growth retar-
dation and a congenital reduction in nephron number,17 in
endothelial dysfunction,31 and in inflammation.8–10 Unpub-
lished studies in our laboratory also suggest it may have a
contributory role in acute renal failure, possibly through its
vasoconstrictive and proinflammatory effects.
CONCLUSION
It is evident that more studies on the role of uric acid in
cardiovascular and renal disease are required. In particular,
identifying the conditions under which uric acid may be
beneficial versus deleterious are critical. Whether uric acid
represents ‘King Priam’s treasure’ and is at the core of the
cardiovascular and renal epidemic is an exciting possibility
but remains to be proven. Regardless, it is clear that the
unearthing of this ancient factor will provide new insights
into cardiovascular and renal biology.
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